中文 / CN
Deutsch / DE
日本語 / JP
한글 / KR
Contact Us
菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button ps_marketing@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button
CRO Services
Drug Development Expertise Empowering Research Services for Biologics

Protein Engineering & Production Services

Your One-Stop Solution for Research Protein Production & Engineering

At WuXi Biologics, our CRO Services specializes in protein production & engineering for various biologics, such as monoclonal, bispecific, and multi-specific antibodies, fusion-proteins, cytokines, enzymes, and novel modalities. With industry-leading expertise, state-of-the-art facilities and proprietary technologies, we offer our customers high-quality protein design, engineering, and production services for research use. Our commitment to continuous innovation and quality is reflected in our track record of success, making us a trusted partner for companies around the world.

Key Features:

  • High-Titer Expression: Harnessing the latest advancements in biotechnology, we excel in achieving high-titer expression of antibodies and proteins.
  • Premium Quality: Our team of experts are comprised of skilled scientists who are well-versed in both engineering and production of proteins. With our rigorous quality control measures throughout the production process, we ensure consistent and reliable results.
  • Speedy Turnaround: With our high-titer expression platform and optimized operation processes, we can deliver your antibodies in just 3 weeks.
  • Cost-effective Solutions: Empowered by our high-titer expression platform, we achieve the same amount of products with a much smaller culture volume and a shorter production time, which translates to the low cost to our customers.

 

Protein Sciences: One-Stop, Modular Services for Research Protein Production

One-stop solution for protein and antibody production covering gene synthesis, antibody/protein expression, antibody/protein purification and antibody/protein characterization; Extensive experiences in various modalities including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, Fc-fusion proteins, antibody fragments (Fab/scFv/VHH) and recombinant proteins.

 

From traditional monoclonal antibodies to innovative bispecific antibodies, various antibody fragments such as Fab fragments, VHH, and scFv, and recombinant proteins, we synergize our drug-making knowledge with antibody and protein production to deliver unparalleled results, ensuring that our clients receive top-tiered biologics to drive groundbreaking research and therapeutic advancements.

Scientist producing antibodies and proteins for research use.

 

Different Services for Different Stages of Antibody Discovery

Backed by extensive biologics drug development expertise, we offer high-titer, high-purity antibody & protein production services for research use.

With expertise in biologics drug development, we offer high-titer, high-purity antibody and protein production services with developability testing for research using Wuxian™ Transient and Wuxian ™ Express platforms

Frequently Asked Questions

Q: Which cell lines are used by WuXi Biologics for antibody production?

A: We primarily use CHO cells for antibody production. We have made significant investments in optimizing our cell engineering and cell growth processes to achieve high titer expression of antibodies in the CHO cells, enhancing the antibody production efficiency.

Q: How long does it typically take to produce antibodies with WuXi Biologics?

A: The antibody production timeline varies depending on several factors, including the type of antibody, the scale of production, and specific client requirements. Using our HTP platforms and high titer expression CHO cells, the timeline could be as fast as 2 weeks, with a daily throughput of 1,000+ molecules.

Q: What makes WuXi Biologics’ antibody & protein production unique?

A: Our unique advantage lies in providing valuable insights and guidance to customers throughout the entire antibody drug development process, enabling them to navigate around common pitfalls and overcome challenges effectively. This comprehensive end-to-end viewpoint and approach ensures a seamless and speedy journey from concept to market, making us a trusted and reliable partner for customers in need of antibody production services.

Q: How do I choose the right expression system (CHO, HEK293 or NS0) for my project?

A: For projects involving new molecules, CHO cells are your ideal choice because of our well-established ultra-high-titer CHO expression platform. For projects encountering issues like truncation issues, HEK293 cells are recommended. In cases where your molecules have severe aggregation issues caused by disulfide bonds in CHO or HEK293, NS0 cells can be considered as a last option.

Q: What makes a good host for producing therapeutic antibodies?

A: An optimal host expresses target antibodies with high titers, optimal glycosylation modifications, low levels of N-linked mannose-5 glycan and afucosylation, and minimal truncations. Additionally, the host should demonstrate efficient transfection, low lactate level, and rapid doubling time.

Q: Are there risks in switching my therapeutic antibody production from HEK293 to CHO?

A: These potential risks include titer variations and different glycosylation and other PTMs, sometimes truncations. The difference may lead to inconsistent efficacy, PK, challenging CMC and late-stage developments. For molecules with therapeutic purposes, it’s highly desirable to use the same CHO host from early discovery to commercial manufacturing.

Q: Why do we need ADCC?

A: Antibody-dependent cellular cytotoxicity (ADCC) is one of the most important effector mechanisms of tumor-targeting antibodies. The need for ADCC depends on the specific therapeutic strategy and mechanism of action (MOA) of your molecule. You may leverage our CHO-Fut8 technology to enhance ADCC effects.  On the other hand, sometimes ADCC effects must be eliminated, such as T-cell engagers. Antibodies can be engineered to reduce or increase the ADCC effect. Consult our specialists for unique requirements of your project.

Q: Should I consider afucosylation for my antibodies?

A: Afucosylation involves the reduction or removal of fucose in the Fc region of an antibody. This modification can significantly boost the antibody’s affinity for FcγRIIIa on natural killer (NK) cells, which in turn enhances ADCC. Careful MOA studies must be carried out to make the decision. You need to find a balance between efficacy and toxicity.

Q: How does WuXi Biologics’ drug development expertise contribute to antibody & protein production?

A: We have cultivated a rich pipeline comprising various drug modalities, including regular mAb, ADC, bsAb and fusion proteins. Leveraging our extensive experience, we can assist clients during the early research stage and accumulate valuable insights into the developability of different modalities. While we primarily focus on research-grade antibodies, WuXi Biologics’ extensive drug development expertise allows us to guide clients through a smooth transition from research to CMC.

More FAQs

Your Project. Our Expertise.

Contact Us